Urinalysis Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Urinalysis Market Trends and Insights

Rising Prevalence of Chronic Kidney Diseases

Worldwide, an estimated 788 million people live with CKD, and 14% of U.S. adults carried a diagnosis in 2024.^{[1]National Kidney Foundation, “Chronic Kidney Disease,” kidney.org} Quarterly or semi-annual urine screening for proteinuria and hematuria has therefore become standard for diabetics and hypertensives. Hospitals and diagnostic chains rely on analyzers that process 240–480 samples per hour, reducing labor costs and enabling same-day clinical intervention. Rapid hub-and-spoke expansion in India’s tier-2 and tier-3 cities channels additional volumes to centralized labs. Recurring reagent revenue rises with every mandated follow-up but faces reimbursement caps when public insurers fix per-test fees.

Growing Diabetic Population Necessitating Routine Urine Testing

The International Diabetes Federation counted 537 million adults with diabetes in 2024 and expects the figure to top 640 million by 2030.^{[2]International Diabetes Federation, “IDF Diabetes Atlas,” idf.org} Urinalysis detects microalbuminuria early in diabetic nephropathy and monitors glycosuria in uncontrolled patients. Public insurers favor preventive testing to avoid late-stage complications, yet India’s Ayushman Bharat program under-reimburses private hospitals, prompting a shift toward lower-cost pharmacy and home testing. Vendors pairing glucose and albumin strips with Bluetooth readers have secured contracts in community health centers across South Asia and the Middle East.

Shift Toward Automated, High-Throughput Platforms

Fully automatic analyzers, such as Siemens Healthineers’ CLINITEK Novus, cleared in Europe in 2025, process 240 specimens per hour and self-validate strip integrity. U.S. laboratories purchase these systems to offset wage inflation and to address a projected 2% growth in technician headcount amid looming retirements. Chinese hospitals prefer domestically made units, buying at an average RMB 53,300 (USD 7,400) and bundling reagents to meet centralized tender rules. Mid-tier facilities still choose semi-automated units ranging from 60 to 240 tests per hour, balancing capital budgets with daily volume.

Integration of AI-Powered Image Analysis for Sediment Examination

IBM and Beckman Coulter have demonstrated convolutional neural networks that identify cells, crystals, and casts with accuracy rivalling expert technicians. Beckman’s DxU Iris Workcell cuts manual review below 3%, improving consistency across shifts.^{[3]Beckman Coulter, “DxU Iris Workcell,” beckmancoulter.com} The U.S. FDA’s 2024 software cybersecurity guidance accelerated 510(k) submissions by defining threat-mitigation protocols. Japan’s 2024 reimbursement handbook for software-as-a-medical-device signals Asia-Pacific support, although capital intensity remains a barrier for rural hospitals.

Reimbursement Gaps Across Emerging Markets

Public insurance programs often reimburse below the cost of reagents, discouraging private investment. Only 13% of private hospitals in a 2025 Maharashtra survey accepted Ayushman Bharat rates, pushing patients toward public facilities or cash payments. WHO noted that low- and middle-income countries spend less than 5% of their health budgets on diagnostics. Suppliers pivot to low-cost strips, but margins remain tight and distribution fragmented.

Shortage of Skilled Laboratory Technicians

The U.S. had 351,200 technologists in 2024, with 44% of staff experiencing burnout. Vacancy rates force hospitals to outsource or delay reporting, harming patient throughput. Automation reduces repetitive tasks yet still needs qualified operators for maintenance. Europe and Japan face similar staffing gaps, complicated by aging workforces and restrictive immigration policies.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Consumables Anchor Revenue, Point-of-Care Devices Accelerate

Consumables generated 49.82% of urinalysis market revenue in 2025, underscoring the lock-in created by proprietary reagent strips calibrated for specific analyzers. Automated analyzers split into fully automatic workcells serving core laboratories and semi-automatic benchtop units addressing 60–240 daily tests. The urinalysis market for consumables is projected to grow steadily, even as pricing pressure from centralized procurement compresses per-test margins. Hospitals in China paid an average of RMB 53,300 (USD 7,400) for fully automatic analyzers during 2024 tenders, favoring domestic brands that bundled reagents and service contracts.

Point-of-care devices grow at a 7.06% CAGR through 2031 as pharmacies and home-health programs adopt smartphone-linked readers and microfluidic cartridges. Instruments segment revenue benefits from capital purchases of CLINITEK Novus and DxU Iris platforms, which integrate strip analysis with digital microscopy and AI particle recognition. Semi-automated analyzers remain relevant in tier-2 hospitals across India and Latin America, where budgets are tight. Veterinary clinics and companion-animal hospitals are a niche but expanding outlet, adding incremental demand for consumables as pet ownership rises.

By Test Type: Biochemical Dominance Meets Infectious-Disease Surge

Biochemical panels accounted for 46.27% of the urinalysis market share in 2025, driven by glucose, protein, and pH strips ordered for routine diabetes and renal assessment. However, infectious-disease detection is the fastest-growing category, expected to reach a 9.63% CAGR through 2031 as antimicrobial-resistance surveillance mandates rapid pathogen identification. The urinalysis market for infectious-disease applications is growing rapidly as primary-care clinics deploy 30-minute UTI point-of-care kits that reduce empirical antibiotic use.

Sediment analysis still commands meaningful revenue but shifts toward AI-enabled digital microscopy that standardizes findings and reduces technician variability. Pregnancy and fertility tests retain volume but face commoditization, with retail prices under USD 10 per kit. Drug-of-abuse testing received a policy boost when SAMHSA added oral-fluid alongside urine in May 2024 guidelines, yet employers continue to favor multi-panel urine screens for cost and historical comparability.

By End User: Hospitals Lead, Home-Care Settings Gain Momentum

Hospitals accounted for 39.79% of the urinalysis market revenue in 2025, supported by mandatory pre-operative screening and emergency-room triage protocols. Diagnostic laboratories form the next-largest group, processing outsourced samples from physician offices through hub-and-spoke networks. The urinalysis market size in home-care settings is forecast to expand fastest at an 8.18% CAGR through 2031 as connected devices like Withings U-Scan achieve FDA 510(k) clearance and GDPR compliance. Academic and research institutes consume smaller volumes but propel biomarker discovery for oncology.

Veterinary clinics contribute incremental growth, with IDEXX Laboratories booking USD 941 million in diagnostic revenue in Q3 2024. Hospitals invest in CLINITEK Novus workcells to manage morning surges, while reference laboratories compete on test menus and ISO 15189 accreditation to attract physician referrals. Home adoption is restrained by privacy legislation, but vendors that encrypt data and offer cloud dashboards capture early adopters.

Geography Analysis

North America accounted for 36.78% of the urinalysis market share in 2025, owing to established reimbursement pathways and early uptake of AI sediment platforms. The FDA’s 2024 cybersecurity guidance clarified 510(k) routes, speeding commercial launches. Workforce shortages drive hospitals to automate, aligning with capital spend on high-throughput analyzers. Canada invests through provincial screening initiatives, whereas Mexico increases private-sector laboratory chains focused on diabetes monitoring. Reimbursement cuts temper revenue, but rising preventive-health volumes partly offset price erosion.

Asia-Pacific is the fastest-growing region, with a 9.28% CAGR projected for 2026-2031. China’s centralized tenders shifted volumes toward domestically produced analyzers from Youlite, Dirui, and Mindray, whose integrated reagent offers secured 73.61% of 2024 contract value. Japan maintains a mature market with 11% of Eiken Chemical’s 2023 revenue from urinalysis strips, and the 2024 MoH guidebook supports software-as-a-medical-device reimbursement. Australia and South Korea are quickly adopting connected home devices due to their robust telemedicine infrastructure.

Europe holds a significant stake thanks to universal coverage and the enforcement of ISO 15189. Germany and the United Kingdom lead automated-analyzer uptake, while GDPR raises compliance hurdles for cloud-connected devices. Eastern European hospitals modernize under EU health-fund grants, yet constrained budgets limit premium analyzer penetration. Latin America and the Middle East & Africa contribute smaller portions but register steady growth as private hospitals expand diagnostics capacity, although currency volatility and fragmented reimbursement pose ongoing risks.

Regulatory Landscape

Urinalysis instruments and reagent test systems sold as IVD medical devices are regulated in the United States under FDA device frameworks that include 21 CFR Part 862 (clinical chemistry and related systems), with categories covering creatinine, urinary protein/albumin, and automated urinalysis systems. Market access commonly requires FDA 510(k) clearance with appropriate labeling and clinical performance evidence, while many routine strip-based tests used outside high-complexity labs also rely on CLIA complexity categorization, including CLIA-waived pathways for certain UTI-related tests.

A key compliance shift for manufacturers is the FDA Quality Management System Regulation (QMSR) update aligning with ISO 13485:2016, effective February 2, 2026, which drives quality-system updates across design controls, manufacturing, and postmarket processes. In Europe, connected and software-enabled urinalysis workflows also intersect with privacy and data-handling expectations under GDPR, and laboratories continue to use ISO 15189 accreditation as a quality anchor for routine urinalysis operations and outsourcing decisions.

Market Opportunities and Future Outlook

Workflow automation and digitally enabled urinalysis create whitespace in settings dealing with staffing constraints and rising screening volumes, particularly where high-throughput analyzers can reduce manual review to below 3% and standardize sediment interpretation using AI image analysis. Suppliers that pair instruments with consumables and connectivity (LIS integration, cybersecurity documentation, and audit-ready traceability) can differentiate in hospital and reference-lab tenders that remain price disciplined, including China-style centralized procurement that favors bundled reagent and service offers from domestic and multinational vendors.

Decentralized and at-home testing is an active opportunity area as regulatory clarity improves for device quality systems and connected-device validation, including the FDA QMSR effective February 2026. Several urinalysis-adjacent clearances also signal sustained U.S. throughput demand for urine-based panels, such as FDA 510(k) clearances for multi-drug urine test panels in January 2026 and May 2026. In Europe, the IVDR transition and the May 28, 2026 activation of multiple EUDAMED modules increase the value of strong clinical evidence packages, UDI/device registration readiness, and compliant cloud architectures for tele-urinalysis, which can help vendors scale across health systems with less added manual documentation burden.